Amir A Jazaeri

List of Publications by Year
in descending order

90	5,064	159585 30	95266 68
papers	citations	h-index	g-index

92	92	92	7252
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunology Research, 2022, 10, 259-271.	3.4	10
2	Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors. Science Advances, 2022, 8, eabm1032.	10.3	35
3	Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis. Gynecologic Oncology, 2022, 165, 664-670.	1.4	7
4	First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS2679-TPS2679.	1.6	1
5	A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.. Journal of Clinical Oncology, 2022, 40, 5522-5522.	1.6	6
6	The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Investigational New Drugs, 2021, 39, 829-835.	2.6	8
7	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Scientific Reports, 2021, 11, 3667.	3.3	20
8	Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. Cancers, 2021, 13, 946.	3.7	31
9	Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer. Cancer Discovery, 2021, 11, 560-574.	9.4	12
10	A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. PLoS ONE, 2021, 16, e0247905.	2.5	20
11	SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment. Cancers, 2021, 13, 1777.	3.7	13
12	Pulmonary resection for tissue harvest in adoptive tumorâ€infiltrating lymphocyte therapy: Safety and feasibility. Journal of Surgical Oncology, 2021, 124, 699-703.	1.7	2
13	Safety and efficacy of percutaneous transabdominal and transesophageal decompression gastric catheters for palliation of malignant bowel obstruction. Abdominal Radiology, 2021, 46, 4489-4498.	2.1	5
14	Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecologic Oncology, 2021, 162, 24-31.	1.4	20
15	Expression of B7â€“H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Human Pathology, 2021, 113, 20-27.	2.0	13
16	Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecologic Oncology, 2021, 162, 65-71.	1.4	3
17	Recruiting for diversity in immunotherapy trials for breast and gynecologic cancers: moving beyond under-representation. International Journal of Gynecological Cancer, 2021, 31, 1408-1409.	2.5	1
18	Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clinical Cancer Research, 2021, 27, 6354-6365.	7.0	31

#	Article	IF	Citations
19	Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. International Journal of Gynecological Cancer, 2021, 31, 92-97.	2.5	3
20	Immuno-Oncology for Gynecologic Malignancies. Advances in Experimental Medicine and Biology, 2021, 1342, 193-232.	1.6	1
21	Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecologic Oncology, 2020, 157, 161-166.	1.4	106
22	A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs. Journal of Cancer Education, 2020, , 1.	1.3	1
23	Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecologic Oncology, 2020, 158, 570-575.	1.4	43
24	Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Reports, 2020, 31, 107502.	6.4	69
25	Immuno-oncology for Gynecologic Malignancies. Advances in Experimental Medicine and Biology, 2020, 1244, 149-182.	1.6	1
26	Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer. Cancer Research, 2019, 79, 4599-4611.	0.9	39
27	Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. Cancer Immunology, Immunotherapy, 2019, 68, 1747-1757.	4.2	16
28	Long-Chain Acyl-CoA Synthetase 1 Role in Sepsis and Immunity: Perspectives From a Parallel Review of Public Transcriptome Datasets and of the Literature. Frontiers in Immunology, 2019, 10, 2410.	4.8	33
29	B-cell acute lymphoblastic leukemia/lymphoma in relapse presenting as a cervical mass: A case report and review of literature. Gynecologic Oncology Reports, 2019, 29, 94-97.	0.6	3
30	Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. Cancer Immunology, Immunotherapy, 2019, 68, 1515-1526.	4.2	14
31	Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. Gynecologic Oncology, 2019, 155, 237-244.	1.4	48
32	Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. , 2019, 7, 118.		26
33	Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitorâ€“induced colitis. , 2019, 7, 93.		131
34	Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. , 2019, 7, 31.		94
35	Sunset, or dawn of a new age for ovarian cancer vaccine therapy?. Gynecologic Oncology, 2019, 155, 387-388.	1.4	0
36	An image informatics pipeline for imaging mass cytometry to characterize the immune landscape in pre- and on-treatment immune therapy and its application in recurrent platinium-resistant epithelial ovarian cancer. , 2019, , .		2

#	Article	IF	Citations
37	Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Frontiers in Immunology, 2018, 9, 2102.	4.8	33
38	Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecologic Oncology, 2018, 151, 407-413.	1.4	17
39	A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecologic Oncology, 2018, 151, 374-380.	1.4	1
40	Potential immunotherapy targets in recurrent cervical cancer. Gynecologic Oncology, 2017, 145, 462-468.	1.4	19
41	Immunotherapy in Gynecologic Cancers: Are We There Yet?. Current Treatment Options in Oncology, 2017, 18, 59.	3.0	45
42	Erythema nodosumâ€like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapyâ€"Report of 2 patients. Journal of Cutaneous Pathology, 2017, 44, 1080-1086.	1.3	48
43	Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. Frontiers in Immunology, 2017, 8, 689.	4.8	55
44	Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10	2.0	17
45	MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Statistics in Medicine, 2016, 35, 3892-3906.	1.6	34
46	Sub-terahertz vibrational spectroscopy for microRNA based diagnostic of ovarian cancer. Convergent Science Physical Oncology, 2016, 2, 045001.	2.6	8
47	Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecologic Oncology, 2016, 141, 86-94.	1.4	26
48	Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia. Neoplasia, 2015, 17, 826-838.	5.3	20
49	Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget, 2015, 6, 30194-30211.	1.8	14
50	Abstract 3912: GDF2 promotes anoikis susceptibility in ovarian and breast epithelia. , 2015, , .		0
51	SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. Genome Biology, 2014, 15, 443.	8.8	59
52	Inhibition of Î±4Î²1 integrin increases ovarian cancer response to carboplatin. Gynecologic Oncology, 2014, 132, 455-461.	1.4	31
53	Two Methods for Establishing Primary Human Endometrial Stromal Cells from Hysterectomy Specimens. Journal of Visualized Experiments, 2014, , .	0.3	10
54	Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924. Molecular Cancer Therapeutics, 2013, 12, 1958-1967.	4.1	60

#	Article	IF	Citations
55	Vulvar necrotizing soft tissue infection: A review of a multi-disciplinary surgical emergency and management in the modern era. Gynecologic Oncology Case Reports, 2013, 5, 6-9.	0.9	7
56	Abstract 3380: Overcoming platinum resistance in ovarian cancer using the novel compound MLN4924.. , 2013, , .		0
57	Frailty: An outcome predictor for elderly gynecologic oncology patients. Gynecologic Oncology, 2012, 126, 20-24.	1.4	112
58	Molecular Requirements for Transformation of Fallopian Tube Epithelial Cells into Serous Carcinoma. Neoplasia, 2011, 13, 899-IN16.	5.3	66
59	A nomogram for estimating the probability of ovarian cancer. Gynecologic Oncology, 2011, 121, 2-7.	1.4	12
60	Temozolomide in Advanced and Recurrent Uterine Leiomyosarcoma and Correlation With O6-Methylguanine DNA Methyltransferase Expression. International Journal of Gynecological Cancer, 2010, 20, 120-125.	2.5	19
61	Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report. Cancer Chemotherapy and Pharmacology, 2010, 66, 265-267.	2.3	8
62	Evaluation of EVI1 and EVI1s (Î”324) as potential therapeutic targets in ovarian cancer. Gynecologic Oncology, 2010, 118, 189-195.	1.4	24
63	Appendiceal Pathology at the Time of Oophorectomy for Ovarian Neoplasms. Obstetrics and Gynecology, 2010, 116, 1348-1353.	2.4	24
64	The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle, 2010, 9, 4387-4398.	2.6	152
65	CRL4Cdt2 E3 Ubiquitin Ligase Monoubiquitinates PCNA to Promote Translesion DNA Synthesis. Molecular Cell, 2010, 37, 143-149.	9.7	135
66	The promise of antiangiogenic therapy for ovarian cancer. Cancer Biology and Therapy, 2009, 8, 2271-2272.	3.4	3
67	Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease. Molecular Oncology, 2009, 3, 151-156.	4.6	21
68	A Clinical and Biological Comparison Between Malignant Mixed MÃ¼llerian Tumors and Grade 3 Endometrioid Endometrial Carcinomas. International Journal of Gynecological Cancer, 2009, 19, 261-265.	2.5	28
69	Utilization of a uniform grading system for interpreting serous ovarian cancer. American Journal of Obstetrics and Gynecology, 2008, 199, 189.e1-189.e6.	1.3	7
70	A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma. Gynecologic Oncology, 2008, 108, 77-83.	1.4	23
71	Cyclooxygenase-2 in cervical neoplasia: A review. Gynecologic Oncology, 2008, 109, 140-145.	1.4	44
72	Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opinion on Pharmacotherapy, 2007, 8, 2293-2305.	1.8	22

#	Article	IF	Citations
73	Cervical adenocarcinoma in situ: the predictive value of conization margin status. American Journal of Obstetrics and Gynecology, 2007, 197, 195.e1-195.e8.	1.3	20
74	Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. American Journal of Obstetrics and Gynecology, 2007, 197, 199.e1-199.e5.	1.3	43
75	Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed mÃ¼llerian tumors. American Journal of Obstetrics and Gynecology, 2006, 194, 1119-1126.	1.3	19
76	Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. American Journal of Obstetrics and Gynecology, 2006, 195, 568-574.	1.3	51
77	The utility of HPV DNA triage in the management of cytological AGC. American Journal of Obstetrics and Gynecology, 2005, 193, 559-565.	1.3	37
78	Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers. Clinical Cancer Research, 2005, 11, 6300-6310.	7.0	175
79	BRCA1-mediated repression of select X chromosome genes. Journal of Translational Medicine, 2004, 2, 32.	4.4	22
80	Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Molecular Carcinogenesis, 2003, 36, 53-59.	2.7	83
81	Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10393-10398.	7.1	1,796
82	Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clinical Cancer Research, 2003, 9, 4811-8.	7.0	73
83	Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers. Journal of the National Cancer Institute, 2002, 94, 990-1000.	6.3	260
84	Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Research, 2002, 4, R3.	5.0	186
85	Core Biopsies Can Be Used to Distinguish Differences in Expression Profiling by cDNA Microarrays. Journal of Molecular Diagnostics, 2002, 4, 30-36.	2.8	41
86	Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene, 2001, 20, 6965-6969.	5.9	52
87	Expression of Estrogen Receptor Î± mRNA and Protein Variants in Human Endometrial Carcinoma. Gynecologic Oncology, 1999, 74, 38-47.	1.4	38
88	Estrogen Receptor mRNA Splice Variants in Pre- and Postmenopausal Human Endometrium and Endometrial Carcinoma. Gynecologic Oncology, 1997, 65, 149-157.	1.4	31
89	The development of serotonergic projections to the olfactory bulb of Monodelphis domestica (the) Tj ETQq1 1 0.784314 rgBT /Overlock	1.7	17
90	Olfactory bulb organization and development in Monodelphis domestica (grey shortâ€tailed) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	48